Time for a new IMU thread!, page-23

Hi @supertramp

Sorry but I think that the HER-vaxx trial also included local disease just like the Herceptin one. From the HER-vaxx inclusion criteria:

"Metastatic gastric or GEJ adenocarcinoma, or locally advanced disease not amenable to surgical resection"

https://clinicaltrials.gov/ct2/show/NCT02795988

So far there is no data to suggest that HER-vaxx works better than Herceptin. I agree that this is not surprising at this stage given HER-vaxx and Herceptin have the same target ie HER2. We are hoping that the polyclonal antibodies stimulated by HER-vaxx have a more durable effect compared to Herceptin. Time will tell.

Also, I note that the latest Edison research update states:

"The HER2 B-cell vaccines have shown signs of efficacy in clinical studies despite the levels ofpolyclonal anti-HER2 antibodies stimulated by the vaccine being at least an order of magnitudelower than the levels used in anticancer therapy with Herceptin, which also acts on HER2."

https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5b7b7fa50ebbe8b7258f3ac5/1534820272676/Edison+report+final+16aug18.pdf